Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany

OBJECTIVES: The aim was to evaluate the safety and effectiveness of sarilumab in RA patients after inadequate response (IR) to janus kinase inhibitors (JAKi) and tocilizumab. METHODS: The prospective, observational, 24-month single-arm PROSARA study (SARILL08661) is currently running in Germany at 9...

Descripción completa

Detalles Bibliográficos
Autores principales: Tony, Hans-Peter, Feist, Eugen, Aries, Peer Malte, Zinke, Silke, Krüger, Klaus, Ahlers, Jonas, Albrecht, Inka, Barrionuevo, Christian, Kalus, Stefanie, Burkhardt, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Concise Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824706/
https://www.ncbi.nlm.nih.gov/pubmed/35146322
http://dx.doi.org/10.1093/rap/rkac002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824706/
https://www.ncbi.nlm.nih.gov/pubmed/35146322
http://dx.doi.org/10.1093/rap/rkac002

Ejemplares similares